Articles from May 2009 ↓

The Dermatology Times is running an article highlighting the novel and unlikely rosacea treatments based on a nasal decongestant and a glaucoma treatment. They of course are referring to Oxymetazoline and Brimonidine. The article mentions the positive results from the “most recent research” on Brimonidine ; In the most recent research, a double-blind study for Galderma, a 1 g application …

An interesting looking patent that was filed in 2006 has come up as reaching filed status. This patent covers the relationship between an oligosaccharide specific to an inflammatory disease, more specifically ocular rosacea. The discovery may lead to both a definitive diagnostic test and new treatments for ocular rosacea. One of inventors of this patent is well known to rosacea sufferers. Dr. Mark Mannis …

Some interesting comments from KUNC commentator Dr. Marc Ringel via a NPR segment. He raises two points that are worth discussing. Firstly is Oracea really any better than generic doxycycline and secondly what does it say about the pharmaceutical industry (and insurance companies – ed) that a repackaged old product  can be so expensive ? Galderma would say that Oracea is sub-antimicrobial …

A couple of recently awarded patents look both interesting and slightly scary for potential rosacea treatments. These patents cover some kind of device that is stuck to the skin. A small electric charge is used to help an active chemical cross the skin barrier. Some kind of carrier (an electrolyte) allows Zinc ions to flow between the electrodes, across the skin, creating a small charge. …

A recent abstract from Dermatologic Surgery suggests that treatment with 590nm LED therapy following fractional laser skin resurfacing helps patients more quickly recover from the post treatment erythema. Whilst skin resurfacing with a laser is considered dangerous for rosacea sufferers, the fact that LED therapy help speed up recovery is good news for LED and low level light therapy in general. The study showed that …